Celldex Therapeutics Company Profile (NASDAQ:CLDX)

Analyst Ratings

Consensus Ratings for Celldex Therapeutics (NASDAQ:CLDX) (?)
Ratings Breakdown: 5 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $14.11 (202.81% upside)

Analysts' Ratings History for Celldex Therapeutics (NASDAQ:CLDX)
Show:
DateFirmActionRatingPrice TargetActions
6/7/2016Cowen and CompanyReiterated RatingOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016WedbushReiterated RatingNeutral$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/6/2016Jefferies GroupReiterated RatingHold$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/19/2016Roth CapitalReiterated RatingBuy$7.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016Brean CapitalReiterated RatingBuy$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/8/2016HC WainwrightLower Price TargetBuy$25.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016Leerink SwannDowngradeOutperform -> Market Perform$30.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016Oppenheimer Holdings Inc.DowngradeOutperform -> Market PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/7/2016GuggenheimDowngradeBuy -> NeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2016Cantor FitzgeraldLower Price TargetBuy$31.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2015WBB SecuritiesReiterated RatingBuy$30.00 -> $40.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/26/2014 forward)

Earnings

Earnings History for Celldex Therapeutics (NASDAQ:CLDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/5/2016Q1 16($0.35)($0.35)$1.06 million$1.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/25/2016Q415($0.35)($0.33)$0.80 million$1.80 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q3($0.35)($0.32)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.34)($0.33)$2.20 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2015Q115($0.36)($0.33)$0.52 million$0.49 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/24/2015Q314($0.35)($0.36)$0.49 million$1.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014Q3($0.31)($0.31)$0.43 million$1.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2014Q214($0.32)($0.32)$0.38 million$0.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/1/2014($0.25)($0.33)$0.34 million$0.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2014Q413($0.28)($0.27)$0.27 million$0.62 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.24)($0.29)$0.09 million$1.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/6/2013Q2 2013($0.22)($0.24)$1.57 million$0.97 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013($0.22)($0.23)$2.65 million$2.41 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2013Q4 2012($0.25)($0.27)$2.45 million$3.65 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2012Q312($0.24)($0.25)$2.07 million$3.11 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2012($0.25)($0.23)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012($0.25)($0.27)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/7/2012($0.26)($0.29)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celldex Therapeutics (NASDAQ:CLDX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20166($0.39)($0.34)($0.36)
Q2 20167($0.39)($0.29)($0.34)
Q3 20167($0.38)($0.27)($0.32)
Q4 20167($0.39)($0.20)($0.31)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celldex Therapeutics (NASDAQ:CLDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celldex Therapeutics (NASDAQ:CLDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
11/23/2015Avery W. CatlinCFOSell25,000$18.00$450,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/25/2015Larry EllbergerDirectorBuy5,000$14.00$70,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/20/2015Larry EllbergerDirectorBuy5,000$15.00$75,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/18/2015Larry EllbergerDirectorBuy5,000$15.95$79,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Anthony S MarucciCEOBuy5,800$16.81$97,498.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Larry EllbergerDirectorBuy5,000$16.59$82,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015Avery W CatlinCFOSell25,000$24.59$614,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013Avery CatlinCFOSell183,333$24.50$4,491,658.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/6/2013Larry EllbergerDirectorSell17,728$24.50$434,336.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Celldex Therapeutics (NASDAQ:CLDX)
DateHeadline
07/25/16 02:28 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Declines ... - Review Fortune
07/23/16 07:30 AMBiotech news that matter for investors: Celldex Therapeutics, Inc. (NASDAQ:CLDX), bluebird bio, Inc. (NASDAQ:BLUE) - The Voice Registrar
07/22/16 03:16 PMStocks on the Move: Polaris Industries Inc. (PII), Celldex Therapeutics, Inc. (CLDX), First Niagara Financial Group ... - iStreetWire
07/22/16 11:15 AMTime To Put On The Watch List? - Mast Therapeutics, Inc. (NYSEMKT:MSTX), Celldex Therapeutics, Inc. (NASDAQ ... - The Voice Registrar
07/22/16 11:15 AMTrading Examination: Performance check on Celldex Therapeutics, Inc. (NASDAQ:CLDX) - TGP
07/22/16 11:15 AMThis Hot Stock is Trending: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - News Oracle
07/21/16 05:52 AMIntraday Active Biotech Stocks News: Rock Creek Pharmaceuticals, Inc. (OTC:RCPI), Celldex Therapeutics, Inc ... - The Voice Registrar
07/19/16 03:19 PMConsensus Analyst Target Price Check for Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Press Telegraph
07/19/16 03:19 PM2 Biotech Stocks News And Price Trends: Celldex Therapeutics, Inc. (NASDAQ:CLDX), Merrimack Pharmaceuticals, Inc ... - The Voice Registrar
07/19/16 11:26 AM3 Biotech Stocks That Could Soar Over the Next 12 Months -
07/18/16 08:16 AMStock in Positive Territory for the Quarter: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Engelwood Daily
07/18/16 08:16 AMTrading Performance and Target Watch for Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Press Telegraph
07/18/16 08:16 AMHC Stocks Assessment: Celldex Therapeutics, Inc. (NASDAQ:CLDX) Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - share market updates (press release)
07/18/16 08:16 AMStock Performance to Track: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - News Oracle
07/16/16 06:28 AMShares Experiencing a Downtrend: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - TGP
07/14/16 08:42 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX): Stock Review and Performance Update - Press Telegraph
07/14/16 03:20 PMCrowd Rating and Earnings Recap for Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Telanagana Press
07/14/16 03:20 PMTraders Recap: Celldex Therapeutics, Inc. (NASDAQ:CLDX), MGIC Investment Corp.(NYSE:MTG) - NYSE Journal (press release)
07/13/16 05:22 PM5 Things Celldex Therapeutics, Inc. Wants You to Know - This clinical-stage biotech has a burgeoning oncology pipeline. Here's what Celldex wants you to know about it.
07/12/16 08:41 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX): Recent Share Performance Watch - Press Telegraph
07/12/16 07:29 AMActive Stocks in 'How' and 'Why'- Celldex Therapeutics. (NASDAQ:CLDX), MGT Capital Investments (NYSEMKT:MGT ... - Seneca Globe
07/11/16 03:12 PMImpact Score and Stock Sentiment Outlook :Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Press Telegraph
07/11/16 03:12 PMCompany Shares of Celldex Therapeutics (NASDAQ:CLDX) Rally 1.09% - TheFounders Daily
07/11/16 03:01 PMCelldex Therapeutics Initiates Phase 1/2 Clinical Trial of New Product Candidate CDX-014 in Advanced Renal Cell Carcinoma - [GlobeNewswire] - HAMPTON, N.J., July 11, 2016-- Celldex Therapeutics, Inc. announced today that enrollment has opened in its Phase 1/ 2 study of CDX-014 in advanced renal cell carcinoma. CDX-014 is a novel antibody-drug ...
07/10/16 07:54 AMCelldex Therapeutics Incorporated (NASDAQ:CLDX) Shorted Shares Increased By 3.56% - Engelwood Daily
07/08/16 11:14 AMCelldex Therapeutics (CLDX) : Analyst Rating Update - Trade Calls
07/08/16 11:14 AMNews Sentiment and Impact Score Review for :Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Press Telegraph
07/08/16 09:04 AM3 Shocking Biotech Flops of 2016 So Far -
07/07/16 03:01 PMCelldex Therapeutics to Participate in the Cantor Fitzgerald 2nd Annual Healthcare Conference - [GlobeNewswire] - HAMPTON, N.J., July 07, 2016-- Celldex Therapeutics, Inc. announced today that Tibor Keler, Ph.D., Executive Vice President and Chief Scientific Officer, will participate in a fireside chat at the Cantor ...
07/07/16 11:02 AMEarnings Review and Price Target Watch for Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Press Telegraph
07/06/16 09:01 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Recap and Target Check - Engelwood Daily
07/05/16 03:13 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX): Eye on Company Share Performance - Press Telegraph
07/05/16 03:13 PMRecommendation View and Earnings Glance for Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Press Telegraph
07/04/16 03:04 PMStock Sentiment Watch for:Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Press Telegraph
07/03/16 03:03 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX) Impact Score and Stock Sentiment Recap - Press Telegraph
07/01/16 03:15 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX) News Sentiment Recap - Press Telegraph
06/30/16 03:30 PMCompany Target Price Watch: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Telanagana Press
06/30/16 11:03 AMCelldex Therapeutics Incorporated (NASDAQ:CLDX) Short Interest Increased By 3.56% - Engelwood Daily
06/29/16 08:19 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Performance and Session Recap - Engelwood Daily
06/29/16 08:19 PMCurrent Analysts Rating Update: Astrazeneca PLC (NYSE:AZN) , Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Street Updates
06/28/16 08:21 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX): Reviewing Stock Performance - Press Telegraph
06/28/16 08:21 PMFocus Stock Recap for: Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Telanagana Press
06/28/16 08:06 AMCelldex Therapeutics, Inc. (NASDAQ:CLDX) Broker Price Targets For The Coming Week - Fiscal Standard
06/28/16 07:25 AMCelldex Therapeutics, Inc. breached its 50 day moving average in a Bearish Manner : CLDX-US : June 28, 2016 -
06/27/16 03:13 PMEquity Research and Technical Review on Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Press Telegraph
06/27/16 03:13 PMWatching Stock Sentiment for:Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Press Telegraph
06/23/16 04:42 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX): Share Update and Performance Review - Press Telegraph
06/22/16 08:30 PMCelldex Therapeutics, Inc. (NASDAQ:CLDX) Stock Momentum at Critical Inflection Point - CML News
06/16/16 03:15 PMNotable Earnings Analysis: W&T Offshore Inc. (NYSE:WTI), Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Beacon Chronicle
06/16/16 07:38 AMAnalysts Tips to Monitor: Boston Scientific Corporation (NYSE:BSX) , Celldex Therapeutics, Inc. (NASDAQ:CLDX) - Street Updates

Social

About Celldex Therapeutics

Celldex Therapeutics logoCelldex Therapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other difficult-to-treat diseases. The Company is engaged in the development of targeted immunotherapeutics comprised of antibodies, adjuvants and monotherapies and antibody-drug conjugates that treat cancers and other diseases. Its lead drug candidates include rindopepimut also referred to as Rintega and CDX-110 and glembatumumab vedotin also referred to as CDX-011. Its early-stage drug candidates in clinical development, includes varlilumab also referred to as CDX-1127, a fully human therapeutic monoclonal antibody for cancer indications, CDX-1401, a targeted immunotherapeutic for cancer indications and CDX-301, an immune cell mobilizing agent and dendritic cell growth factor. CDX-014 is a preclinical product under development for the treatment of cancer.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CLDX
  • CUSIP: 15117B10
Key Metrics:
  • Previous Close: $4.67
  • 50 Day Moving Average: $4.491
  • 200 Day Moving Average: $5.433
  • P/E Ratio: N/A
  • P/E Growth: 0.000
  • Market Cap: $460.52M
  • Beta: 3.16
  • Current Year EPS Consensus Estimate: $-1.36 EPS
  • Next Year EPS Consensus Estimate: $-1.26 EPS
Additional Links:
Celldex Therapeutics (NASDAQ:CLDX) Chart for Tuesday, July, 26, 2016